CYP19A1 and breast carcinoma: The analysis revealed that Anastrozole, a selective aromatase inhibitor used to treat estrogen-responsive breast cancer, may influence melasma development due to its effect on estrogen levels, given the well-established link between estrogen fluctuations and melasma [22].